Maze Therapeutics, Inc. (MAZE) stock
MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$34.33−1.76 (-4.88%)
Close on Nov 13, 2026Market cap $1.91BP/E –Yield –
Maze Therapeutics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Maze Therapeutics's EPS for the twelve months ending Sep 30, 2026 was -$2.65. For fiscal 2025 it was -$3.05, down 344.0% from the year before.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.05 | -344.0% |
| FY2024 | Dec 31, 2024 | $1.25 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.79 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.76 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.45 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.65 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.66 | -120.5% |
| Q2 FY2025 | Jun 30, 2025 | -$0.77 | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.15 | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.25 | – |
| Q2 FY2024 | Jun 30, 2024 | $3.22 | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.91 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?